Simulations Plus, a provider of model-informed and AI-assisted drug development software, agreed on 16 June to be acquired by affiliates of Altaris for US$18.50 per share in cash, about US$375m.
Why Altaris is buying Simulations Plus, Inc.
Altaris intends to combine Simulations Plus with Chemical Computing Group to create a broader biosimulation platform for drug discovery and development. Simulations Plus said the life sciences software market is shifting towards integrated, AI-driven and subscription-based platforms.
Deal terms and financing
The price is a 26% premium to the 60-day volume-weighted average. The deal is financed with equity and debt from Altaris-affiliated funds and is not subject to a financing condition. Co-founder Walter Woltosz signed a voting and support agreement.
Regulatory approvals and timing
Closing requires shareholder and regulatory approvals and was expected in the fourth quarter of 2026. The company will remain headquartered in Research Triangle Park, North Carolina.
Market context
Altaris, based in New York, invests exclusively in healthcare and manages more than US$9bn of equity capital.
